(R)-2-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

A white to off‑white, low‑melting solid or viscous oil with a molecular weight of 228.31 g·mol⁻¹ and a typical specific rotation [α]_D²⁰ of −28° to −34° (c = 1, MeOH), (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester—systematically named (R)‑tert‑butyl 2‑(aminomethyl)pyrrolidine‑1‑carboxylate—functions as an enantiomerically pure chiral 1,2‑diamine equivalent in which the pyrrolidine nitrogen is masked by an acid‑labile Boc group and the exocyclic primary amine remains free. It is supplied under argon in septum‑sealed glass vials, with tight control over headspace moisture, and is routinely stored at −20 °C because thermal de‑Boc kinetics become measurable above +4 °C in the presence of adventitious protic species. Typical lot analyses report a purity by achiral HPLC (210 nm, C18 column, acetonitrile/0.1 % TFA gradient) of ≥98.5 area‑% and an enantiomeric excess determined on a Daicel Chiralpak IA column (n‑hexane/ethanol/diethylamine 90:10:0.1 v/v/v, 1.0 mL·min⁻¹, 25 °C) of ≥99.0 %, with the (S)‑enantiomer eluting as the faster‑migrating peak under these conditions.

Why does residual moisture in (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester derail peptide couplings run with uronium‑type activation?

In solution‑phase amide bond formation using reagents such as HATU or HBTU, free water in the substrate or solvent drives a competitive hydrolysis cascade that both consumes the activated carboxyl component and erodes the enantiomeric purity of the chiral amine. The primary amine of (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester is intrinsically nucleophilic; when the coupling mixture contains even 0.05 % w/w water—equivalent to roughly 500 ppm—the reactive O‑acyluronium intermediate partitions toward hydrolysis before the target amine can intercept it. This results in a drop in isolated yield, but more critically on a kilo‑laboratory scale the long reaction times required to drive conversion allow the free amine to undergo transient imine formation with trace aldehydes and subsequent equilibration at the α‑position, causing an ee loss of 0.8 – 2.5 % as verified by chiral HPLC of the isolated amide diastereomer pairs. Production‑scale experience on multi‑kilogram batches processed in 100‑L glass‑lined reactors reveals that pre‑drying of the substrate over activated 4‑Å molecular sieves (pre‑activated at 300 °C under 0.1 mbar for 12 h) is mandatory when the ambient relative humidity exceeds 60 %. Even then, the dissolution solvent—usually anhydrous DMF or acetonitrile with water content verified by coulometric Karl Fischer titration to be below 50 µg·g⁻¹ per ISO 760:1978—must be transferred via a nitrogen‑pressurised canula to avoid moisture ingress. Under these rigorous conditions, the coupling of (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester with Fmoc‑protected amino acids proceeds with ≤0.3 % epimerization, a threshold below which subsequent crystallisation of the diastereomerically pure product becomes practical in a cGMP environment governed by ICH Q7 §7.3. An operational boundary that frequently emerges during scale‑up is the acid‑sensitivity of the tert‑butyl carbamate during aqueous work‑up. Washing the reaction mixture with 1 M citric acid to remove residual bases can initiate premature Boc cleavage if the organic phase is allowed to stand for more than 30 min at 20 – 25 °C. In one campaign tracked by in‑process HPLC, a batch left with citric acid contact for 45 min exhibited 4.2 % of the de‑protected diamine, which subsequently formed an intractable bis‑amide impurity. The mitigation protocol—immediate phase separation with a centrifugal extractor operating at 1500 rpm followed by a back‑extraction with cold (5 °C) deionised water—reduced the de‑Boc by‑product to 0.2 %, thereby maintaining overall purity within the ICH Q3A specification for unknown impurities.

Typical lot‑release specifications and corresponding test methods

Parameter	Acceptance Criterion	Analytical Method
Appearance	White to off‑white crystalline solid or clear, colourless oil	Visual inspection against Ph. Eur. 2.2.1
Purity (achiral HPLC)	≥98.5 area‑%	C18, 210 nm, acetonitrile/0.1 % TFA; USP <621>
Enantiomeric excess	≥99.0 %	Chiralpak IA, hexane/EtOH/DEA; USP <621> for system suitability
Water content (Karl Fischer)	≤0.5 % w/w	Coulometric titration per ISO 760
Residual solvents (GC‑HS)	Ethyl acetate ≤5000 ppm, hexane ≤290 ppm	Headspace GC‑FID per USP <467> procedure A
Specific rotation	−28° to −34° (c=1, MeOH, 20 °C)	Polarimetry at 589 nm; Ph. Eur. 2.2.7
Heavy metals	≤20 ppm	USP <231> Method II (or ICP‑MS per ICH Q3D)

When the (R)‑configured building block is compared directly with its (S)‑enantiomer and with the racemic modification, the differences in downstream synthetic utility are governed by more than optical rotation. Both enantiomers share the same achiral purity profile—the same capability to be stored as a viscous oil that solidifies below 10 – 15 °C—yet the (S)‑form often elutes with a retention time 2.0 – 3.5 min earlier on a Chiralpak IA column under the conditions specified above, a divergence that is exploited to verify batch identity in multi‑ton contract manufacturing. The racemic mixture (±)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester, while offered at a lower cost, introduces a statistical diastereomeric mixture during any diastereoselective reaction, lowering the diastereomeric ratio (dr) from a typical level of 95:5 achievable with the single enantiomer to ~50:50 and forcing an additional chiral chromatography step that erases the initial cost advantage. In the synthesis of a clinical‑phase MCH‑1 receptor antagonist, substituting the (R)‑enantiomer with the racemate was documented to reduce the isolated yield of the key advanced intermediate from 72 % to 38 % after one crystallisation, an outcome traced to the mismatched packing of the (S)‑diastereomer in the crystal lattice. Beyond enantiomer comparisons, users evaluate (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester against homologous scaffolds such as the piperidine analogue (2‑aminomethyl‑piperidine‑1‑carboxylic acid tert‑butyl ester) and the acyclic N‑Boc‑diaminoethane. The pyrrolidine ring imposes a gauche‑type conformational lock across the N–C2–C(aminomethyl) bond axis, with the five‑membered ring preferring an envelope pucker that places the aminomethyl substituent pseudo‑equatorially. This geometry lowers the pK_a of the pendant primary amine by approximately 0.3‑0.5 log units relative to the unstrained acyclic analogue, altering the pH‑rate profile of subsequent reductive aminations. In practice, when this building block is used to construct a tertiary amine pharmacophore under sodium triacetoxyborohydride conditions, optimal conversion is observed at pH 5.2 ± 0.3, a window that is 0.4 units narrower than that required for the linear Boc‑ethylenediamine and must be maintained with a glycine‑HCl buffer to avoid over‑reduction of the product.

Chiral purity decay during prolonged ambient storage and the role of head‑group degradation products

Monitoring of retained samples stored in standard screw‑cap vials under argon at −20 °C for 24 months shows no appreciable change in enantiomeric excess; degradation becomes detectable only when the material is repeatedly warmed to 20 °C for in‑process sampling, which introduces enough moisture to hydrolyse the carbamate and liberate the secondary amine. The free pyrrolidine then reacts with atmospheric CO₂ to form a carbamate salt that promotes further racemization through a transient iminium species. A controlled stability study conducted in a 25 °C/60 % RH chamber per ICH Q1A(R2) revealed that after 30 days the (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester lost 1.8 % ee, while the corresponding piperidine analogue lost only 0.6 % under identical conditions, a difference attributed to the higher ring strain of the pyrrolidine that lowers the activation barrier for iminium formation. This accelerated chiral erosion mandates that any process relying on this intermediate for GMP manufacture of an active pharmaceutical ingredient must incorporate a dedicated chiral purity release test on the isolated downstream intermediate, not solely on the incoming raw material. The operational consequence of these stability characteristics is that bulk shipments of (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester—typically packaged in 1‑L or 5‑L aluminium bottles with PTFE‑faced seals—carry a recommended expiry of 12 months when stored continuously at −20 °C, and the receiver is advised to perform an identity check by ¹H‑NMR and a Karl Fischer determination before use if the container has been opened more than twice. Published data for the performance of this specific building block in continuous‑flow peptide synthesis is limited; however, the amine’s nucleophilicity in anhydrous DMF has been measured using a competition reaction with isobutyl chloroformate, giving a relative reactivity ratio of 1.7 compared to N‑Boc‑piperidin‑2‑ylmethylamine, which guides residence‑time selection in micro‑reactor campaigns targeting 0.5 mol·h⁻¹ throughput. Direct fusion of the (R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester unit into a macrocyclic peptide scaffold—such as those explored in antiviral research targeting the hepatitis C NS3/4A protease—depends on tuning the ring‑closure site to avoid cyclisation at the pyrrolidine nitrogen. The Boc group remains intact under the basic macrocyclisation conditions (DMF, HATU, 2,4,6‑collidine, 0 °C to room temperature over 16 h) only when the amine component is pre‑stirred with the coupling agent for at least 5 min before addition of the linear precursor; omitting this pre‑activation step allows the free aminomethyl group to compete as an internal nucleophile, leading to a pyrrolidine‑capped lactam dead end that was identified in LC‑MS with an m/z consistent with a +18 Da shift relative to the desired macrocycle. Process chemists at pilot‑plant scale have encoded this as a sequential addition protocol in a DeltaV™ automated synthesiser to achieve an end‑of‑macrocyclisation crude purity of 84 area‑%, which drops to 52 area‑% when pre‑activation is skipped. The resultant reduction in preparative HPLC loading capacity—from 10 g of crude per injection at 84 % purity to 4 g per injection at 52 %—underscores the need for rigorous adherence to the activation sequence in GMP runs, especially when the column stationary phase is a 5 µm C18 silica in an 50 mm × 250 mm axial compression column operated at 80 bar back‑pressure.

Comparative retention behaviour and conformational properties of closely related building blocks

Compound	Retention time on Chiralpak IA (min)a	Specific rotation (c=1, MeOH)	Lowest‑energy ring pucker
(R)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester	12.8 (major), 15.9 (S‑minor)	−31° ± 3°	Cβ‑exo envelope
(S)-2‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester	15.9	+31° ± 3°	Cβ‑exo envelope
2‑aminomethyl‑piperidine‑1‑carboxylic acid tert‑butyl ester (racemic)	N/A (achiral column: 9.2 min)	—	Chair, N‑Boc equatorial
N‑Boc‑ethylenediamine	N/A (achiral column: 5.6 min)	—	Fully extended anti

^a Conditions: 4.6 × 250 mm Chiralpak IA, n‑hexane/ethanol/diethylamine 90:10:0.1 v/v/v, 1.0 mL·min⁻¹, 25 °C, detection at 210 nm.